SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): January 21, 2003
(State or Other Jurisdiction
(Commission File Number)
|230 Constitution Drive
Menlo Park, California
(Address of principal executive offices)
(Registrants telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
|Item 5. Other Events.|
|Item 7. Exhibits.|
Item 5. Other Events.
On January 21, 2003, Geron Corporation, a Delaware corporation (the Company), announced that it is changing its organization in order to concentrate its resources on the continued development of its lead anti-cancer product, GRN163, and its regenerative medicine products based on human embryonic stem cells (hESCs). In the process, Geron is reducing its research staff by 29 employees and its support staff by 11 employees.
The Companys press release announcing the organizational change is filed as an exhibit to this Current Report on Form 8-K. The summary description of the event is qualified in its entirety by reference to the document filed as an exhibit hereto.
Item 7. Exhibits.
|99.1||Press Release dated January 21, 2003.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: January 22, 2003||By:||/s/ William D. Stempel|
|William D. Stempel
Vice President and General Counsel
|99.1||Press Release dated January 21, 2003|